Protalix Biotherapeutics, Inc. (PLX)

Protalix BioTherapeutics reported its fiscal year 2025 financial and business results, leading to a share decline of 20.8%. Protalix issued a letter to stockholders, providing an update on its focus for 2026, including the advancement of PRX-115 and its strategic focus on rare kidney diseases. The company announced a collaboration and option agreement with Secarna Pharmaceuticals GmbH & Co. KG for RNA-based programs targeting rare renal indications. Protalix BioTherapeutics reported its third-quarter 2025 financial and business results. The stock price experienced a decline of 31.49% between May 8, 2025, and May 7, 2026.

Global ordering patterns for Protalix Biotherapeutics' products, particularly Elfabrio, are expected to fluctuate quarterly as the launch matures and market share expands. While there might be short-term variations in demand, there is no explicit indication of a strong, predictable seasonal demand pattern. The company anticipates that underlying demand characteristics will stabilize over time.

Protalix Biotherapeutics specializes in enzyme replacement therapies for rare diseases, particularly lysosomal storage disorders. Elelyso (taliglucerase alfa) is a recombinant glucocerebrosidase enzyme approved by the FDA for Gaucher disease, with global rights licensed to Pfizer Inc. except in Brazil. Elfabrio (pegunigalsidase alfa) is a plant cell culture-expressed protein approved by the FDA and EMA for Fabry disease, developed and commercialized globally with Chiesi Farmaceutici S.p.A. The company's pipeline includes PRX-115, in Phase 2 clinical trials for uncontrolled gout, and PRX-119, focused on rare kidney disease indications.

Protalix Biotherapeutics is headquartered in Hackensack, New Jersey, and Karmiel, Israel, operating as a single segment in Israel. Elelyso is commercialized worldwide by Pfizer (excluding Brazil), and Elfabrio is globally developed and commercialized with Chiesi Farmaceutici S.p.A. Protalix also has agreements with Fundação Oswaldo Cruz (Fiocruz) for alfataliglicerase (Elelyso) in Brazil.

Protalix Biotherapeutics' brand reputation is shaped by its focus on innovative therapies for rare diseases using its ProCellEx® system. The FDA and EMA approvals of Elfabrio for Fabry disease and the commercialization of Elelyso for Gaucher disease contribute positively to its standing. Updates on its pipeline, such as PRX-115 for gout and the expansion into rare kidney diseases, demonstrate a commitment to addressing unmet medical needs. Financial results can impact investor sentiment, but the company's core mission and scientific advancements underpin its reputation.

Protalix Biotherapeutics has a significant number of institutional owners and shareholders. As of May 5, 2026, 88 institutional owners held a total of 15,697,768 shares. Major institutional owners include BlackRock, Inc., Opaleye Management Inc., Renaissance Technologies Llc, Northern Trust Corp, Geode Capital Management, Llc, State Street Corp, Stratos Wealth Partners, LTD., Vanguard Group Inc, Dimensional Fund Advisors LP, Bank of New York Mellon Corp, Invesco Ltd., and MAK Capital Fund L.P. Key individual owners include Biocell Ltd, Phillip Md Et Al Frost, and Zeev Bronfeld. Other individual owners mentioned include Dror Bashan, Eyal Rubin, and Aharon Schwartz.